Drug
Ce1226
Ce1226: highest development phase Post-Market, developed by CSL. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- CSL
Trials
| Drug | Phase | Indication |
|---|---|---|
| CE1226 NCT07326592 | Post-Market | Alpha1 Antitrypsin Deficiency |
Latest
No recent events.
Follow Ce1226 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.